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Abstract
Purpose To assess the radiation dosimetry and biodistribu-
tion of
99mTc-labeled ethylene dicysteine deoxyglucose
(
99mTc-EC-DG) in patients with non-small-cell lung cancer
(NSCLC).
Methods Serial whole-body scans were acquired 0, 2, 4, 6
and 24 h after injection of
99mTc-EC-DG (925 MBq) in
seven NSCLC patients. Radiation dosimetry, blood clear-
ance and SPECT imaging of the primary tumor were
assessed.
Results The critical organ was the bladder wall, with average
radiation absorbed dose over all seven patients of
2.47×10
−2 mGy/MBq. The average effective dose equivalent
and effective dose were 6.20×10
−3 mSv/MBq (6.89 mSv/
1,110 MBq) and 5.90×10
−3 mSv/MBq (6.54 mSv/
1,110 MBq), respectively. The primary tumor was visualized
with SPECT in six patients. On final pathology, one patient
had a granuloma, which did not enhance with
99mTc-EC-DG.
Conclusion
99mTc-EC-DG has acceptable dosimetric and
biodistribution properties as a diagnostic tumor-imaging
agent. Future studies are planned to evaluate its diagnostic
potential.
Keywords EC-DG.Lungcancer.SPECT.Glucosamine.
Deoxyglucose
Introduction
We report here the radiation dosimetry and biodistribution
of
99mTc-labeled ethylene dicysteine deoxyglucose (
99mTc-
EC-DG) in patients with non-small-cell lung cancer
(NSCLC).
Imaging the tumor accumulation of
18F-FDG with a PET
scan has proven quite useful in the identification of
malignant tumors [1, 2]. It has even been recommended
that
18F-FDG PET data be integrated into planning of
radiation therapy for NSCLC, particularly for three-
dimensional conformal techniques [3, 4]. Unfortunately, a
significant amount (>95%) of
18F-FDG concentrates in the
cytosolic fraction, which results in false-positive findings
and difficulty distinguishing between inflammation or
infection and tumor [5–8].
Our goal was to develop a noninvasive, single photon
emissionCT(SPECT)glucosemetabolismimagingagentthat
couldpotentiallydetectNSCLCtumorsmorespecificallythan
18F-FDG PET. For this purpose, we developed and conju-
gated ethylenedicysteine (EC) with deoxyglucose (DG), and
labeled the resulting agent, EC-DG, with
99mTc [9]. The
molecular structure of
99mTc-EC-DG is shown in Fig. 1.
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e-mail: nschechter@radonc.ucsf.eduThe molecule EC-DG has key position(s) available for
interaction(s). For example, D-glucosamine can be acety-
lated and phosphorylated at positions 2 and 6. EC has two
COO– arms and the two dithiol (SH) locations. During
synthesis, the molecule changes to a peptide linkage with
two glucosamine arms, with EC linked at position 2 at
both sites of the glucosamine. EC retains two dithiols that
can react with glycoproteins and the lumen of the cell
membrane, such as O-linked N-acetylglucosamine [10–
13]. It is likely that S–H bonds of EC-DG bind to
cytosolic and transmembrane enzymes (beta-N-acetylglu-
cosaminidase and O-GlcNAc transferase) or membrane-
associated proteins (O-linked N-acetylglucosamine) which
form (EC-DG)S–S(protein) linkages (docking and fusion)
and support the translocation of EC-DG into the cell
nucleus. It is known that glucosamine is phosphorylated at
positions 1 and 6 and binds with uridine diphospho-N-
acetylglucosamine to form O-linked N-acetylglucosamine
at those same positions that involve nuclear and cytosolic
protein interactions. Recent studies demonstrate a role for
O-GlcNAcylation in processes as diverse as transcription
in the nucleus and signaling in the cytoplasm, suggesting
that O-GlcNAc has both protein and site-specific influen-
ces on biochemistry and metabolism throughout the cell
[10, 11].
Preclinical work evaluating the feasibility of
99mTc-EC-
DG imaging in tumor-bearing rodents has been previously
published [9, 14, 15]. In these studies, EC-DG was
positive for phosphorylation in the hexokinase assay:
blood glucose levels increased following EC-DG injection
and decreased after insulin administration. Scintigraphic
results have demonstrated the feasibility of
99mTc-EC-DG
imaging. Tumor-to-brain tissue and tumor-to-muscle tis-
sue ratios of
99mTc-EC-DG uptake were higher than those
of
18F-FDG uptake, likely due to the overall hydrophilicity
and unique cell internalization properties of
99mTc-EC-
DG. Based on the promising preclinical findings, the US
Food and Drug Administration (FDA) approved a phase I
study in humans. This article is the first report of the
radiation dosimetry and biodistribution of
99mTc-EC-DG
in human subjects. The results of SPECT imaging of the
primary tumor are also reported briefly.
Materials and methods
Synthesis and labeling of
99mTc-EC-DG
99mTc-EC-DG was prepared as described previously [9].
All clinical samples were tested for radiochemical purity
(AR-2000 radio-TLC scanner; Bioscan, Washington, DC),
sterility and pyrogenicity (South Texas Nuclear Pharmacy,
Houston, TX).
Synthesis of EC-DG has been previously reported [9].
Briefly, EC was dissolved in NaHCO3.T ot h i sc o l o r l e s s
solution were added sulfo-N-hydroxysuccinimide (sulfo-
NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide-
HCl (EDAC) (Aldrich Chemical Co., Milwaukee, WI).
D-Glucosamine hydrochloride salt (Sigma Chemical Co.,
St. Louis, MO) was then added. A pH of 8 was measured.
The mixture was stirred at room temperature for 16 h and
then dialyzed for 24 h using Spectra/POR molecular porous
membrane with cut-off at 500 Da (Spectrum Medical
Industries, Houston, TX). After dialysis, the product was
filtered through a 0.45-µm nylon filter and then freeze-dried
using a lyophilizer (Labconco, Kansas City, MO). EC-DG
was labeled with
99mTc in the presence of tin(II) chloride.
99mTc was chelated in the EC core.
Two assays, thin-layer chromatography (TLC) and high-
performance liquid chromatography (HPLC), were used to
determine radiochemical purity. The TLC chromatogram
(ITLC-SG) was scanned for distribution of radioactivity in a
radiochromatogram scanner. Using 1 M ammonium acetate/
methanol (4:1) or saline elution, the retardation factor (Rf) of
99mTc-EC-DG was 0.8. For the HPLC assay,
99mTc-EC-DG
(20 µl, 1 mg/ml EC-DG) was loaded onto a C-18 reverse-
phase column (Waters, semi-prep, 7.8×300 mm) and eluted
with water at a flow rate of 0.5 ml/min. UV absorbance at
210 nm or 272 nm was used to assess the purity of
99mTc-
EC-DG; UV at 210 nm is preferred. We accept a radio-
chemical purity of greater than or equal to 90% as a
specification for the drug product.
Forthepyrogenicityassay,agelclotLALlysatekit(Sigma
Chemical Company, St. Louis, MO) with a sensitivity of
0.125 E. coli units (EU) per milliliter was used to determine
bacterial endotoxins. Drug solution (0.1 ml) was incubated in
vials for 1 h at room temperature. Pyrogenicity was assayed
by visualizing the gel clot in the solution to ensure no more
than 175 EU per 4 ml of the drug injection, in which 1 ml is
the maximum recommended total dose at the expiration time.
To ensure sterility, each batch of product was tested using
culture vials with aerobic and anaerobic materials (NR6 and
NR7; Becton Dickinson Diagnostic Instrument Systems,
Towson, MD). Drug solution (0.3 ml) was incubated in
Bactec culture vials for 7 days at 37°C. Sterility was assayed
by visualizing the cloudiness of the solution.
Fig. 1 Structure of
99mTc-EC-DG
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This study (MDACC ID01-415) was approved by the
M. D. Anderson Cancer Center clinical research commit-
tee, institutional review board, radioactive drug research
committee, and radiation safety committee. It was also
approved by the FDA under (IND) application 63698 held
by Cell>Point LLC (Englewood, CO). The phase I clinical
trial (RO00-311) opened for patient accrual on 30 January
2003. All patients gave their informed consent.
Patient eligibility
Each eligible patient had to be an adult (18 years of age or
older), and have a pathologic diagnosis of NSCLC with no
pathologic evidence of small-cell or bronchioloalveolar
carcinoma of the lung. There was no tumor stage
restriction. None of the patients had undergone mediastino-
scopy, fine-needle aspiration of a mediastinal node, or
biopsy of a mediastinal node. None of the patients had
received radiation therapy to the chest. None of the patients
had received chemotherapy or other treatment for this or
any other lung cancer. Pleural effusion on the most recent
chest radiograph was cause for exclusion. In addition, a
patient was excluded if he or she had a history of: any other
primary cancer, renal insufficiency, hepatic insufficiency,
insulin-dependent diabetes mellitus, or a myocardial infarc-
tion in the 6 months prior to evaluation for study
participation. Patients with a history of skin cancer,
carcinoma in situ of the cervix, or other tumors that had
been in remission for 2 years or longer were considered
eligible.
The FDA recommended the use of
18F-FDG PET
findings as the gold reference standard for comparison of
SPECT findings, since our subjects were to be imaged
with
99mTc-EC-DG before candidacy for definitive surgery
was determined. Therefore, as part of the standard
evaluation, each patient must have had, or have planned
or scheduled within 14 days of consent, an
18F-FDG PET/
CT scan at our institution. A CT scan of the chest with
contrast agent administration had to be planned, sched-
uled, or to have been completed within 30 days of study
consent. As part of the standard evaluation, chest ra-
diography (with anterior-posterior and lateral views),
magnetic resonance imaging (MRI) or CT scan of the
brain with contrast agent administration (when clinically
indicated), and a bone scan (when clinically indicated)
must have been performed within 30 days prior to the
patient’s consent or planned (not necessarily scheduled)
within a 2-week period after consent to this study.
Inability to lie flat and remain still for 45 min was an
exclusion criterion.
Criteria for removal from the study
Criteria for removal from the study included: (1) patient
noncompliance with protocol requirements, (2) unaccept-
able adverse reaction, (3) patient’s wishes, (4) belief that the
constraints of the study were detrimental to the patient’s
health, and (5) inpatient status on day(s) planned for the
99mTc-EC-DG scans.
99mTc-EC-DG imaging
Each patient fasted for at least 8 h prior to the administra-
tion of
99mTc-EC-DG. The last meal before this fast was
recommended to be high in protein and low in carbohy-
drates. Only high-protein low-carbohydrate snacks were
allowed from the time of
99mTc-EC-DG injection until all of
the patient’s whole-body and SPECT study images were
acquired.
Prior to
99mTc-EC-DG administration, anterior whole-
body planar transmission scans of a
57Co sheet source
placed on the posterior detector of a dual-head gamma
camera equipped with low-energy high-resolution (LEHR)
collimators (E.Cam, Siemens Medical Solutions USA,
Hoffman Estates, IL) were acquired at a 10 cm/min scan
speed both without and with the patient in between, for
attenuation correction of the geometric mean regional count
data from the whole-body planar
99mTc-EC-DG scans.
Approximately 925 MBq (25 mCi) of
99mTc-labeled EC-
DG was then injected as a bolus via an antecubital vein,
with the patient lying on the imaging table, followed
immediately by a 5-ml flush of isotonic saline solution.
Simultaneous anterior-posterior whole-body planar scans
were acquired immediately after injection, and then at 2, 4
and 6 h, at a scan speed of 10 cm/min. (The first four
patients were also scanned at 24 h, but a statistical
comparison between residence times calculated with and
without the 24-h scan was performed prior to the fifth
patient, which demonstrated that the 24-h scan could be
eliminated.) The immediate postinjection scan was acquired
prior to micturition, to ensure the total-body image at t=0 h
contained 100% of the administered activity.
SPECTscanning ofthe thorax including the primary tumor
was also performed after each of the 2-, 4- and 6-h whole-
body scans. The acquisition parameters for each SPECTscan
were: LEHR collimation, 120 step-and-shoot views over360°
(60 views per head), 180° noncircular orbit rotation, 128×128
image matrix with a zoom factor of 1 (4.8 mm/pixel
sampling), and 26 s per view (30 min total scan time,
accountingfor the 4-s step time between views). Each SPECT
scan was reconstructed iteratively (10 subsets, 12 iterations,
and two-pixel-wide [9.6 mm FWHM] 3-D gaussian post-
filtering), employing an algorithm that incorporated attenua-
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study that was manually registered to the SPECT, as well as
compensationfor the system resolution of the gamma camera.
Both the PET/CT and SPECT scans were acquired with the
patient positioned in a customized radiation therapy immobi-
lizer, and seven fiducial markers (
57Co spot markers, visible
on both SPECT and CT) were placed on the sternal notch,
clavicles and sides to aid in the task of manual registration.
The reconstructed slices were visually assessed for the
presence of
99mTc-EC-DG in the primary tumor.
The degree of agreement between the two imaging
techniques,
99mTc-EC-DG and
18F-FDG PET, was mea-
sured, with
18F-FDG PET results serving as the reference
standard. If pathologic specimens from the thorax were
obtained within 4 weeks following administration of
99mTc-
EC-DG, then that pathologic information was compared
with the
99mTc-EC-DG and
18F-FDG PET scan results. The
99mTc-EC-DG scans were reviewed blindly and indepen-
dently by a single physician certified by the American
Board of Nuclear Medicine and the American Board of
Radiology (as a diagnostic radiologist with special compe-
tence in nuclear radiology). The reference
18F-FDG PET
scans were reviewed blindly and independently by another
single physician certified by the American Board of
Nuclear Medicine. The diagnostic chest CT scans to be
used as reference for tumor volumes on this study were
reviewed by consensus of two other physicians certified by
the American Board of Radiology. Thoracic pathology
findings to be used for comparison with
99mTc-EC-DG and
18F-FDG PET scan findings in this study were reviewed by
a single physician certified by the American Board of
Pathology.
A tumor-to-background (T:B) ratio was calculated for
each
99mTc-EC-DG SPECT and
18F-FDG PET scan, for
quantitative comparison of tumor uptake. The T:B ratio was
computed from two-dimensional regions of interest (ROIs)
defined on a transverse slice through the center of the tumor
on each scan. A ROI was manually defined around the
tumor, and then a duplicate was generated to serve as the
background ROI. The background ROI was mirrored over
normal tissue in the contralateral lung, unless the contra-
lateral region included non-lung tissue (e.g., upper liver,
blood pool, soft tissue), in which case a nonmirrored region
in the ipsilateral lung was used instead. The T:B ratio was
calculated as the ratio of the tissue count density (
99mTc-
EC-DG SPECT) or average SUV (
18F-FDG PET) in the
two ROIs.
Radiation dosimetry of
99mTc-EC-DG
Radiation absorbed doses to organs from
99mTc-EC-DG
were estimated from geometric mean quantification of the
total-body and organ activities in the serial whole-body
planar emission images. For all imaging time points, ROIs
were manually drawn around the whole body, and each
organ with visible uptake, on both the anterior and posterior
scans. The organs included the kidneys, liver, lungs, spleen,
stomach, testes, thyroid, and urinary bladder contents. A
background ROI near each organ was also defined in order
to be able to subtract superimposed extra-organ activity.
Total background-corrected counts within each anterior and
posterior ROI were calculated, and their geometric mean
was then computed [(anterior counts × posterior counts)
1/2]
[15, 16]. The geometric mean of the total counts was
corrected for attenuation using the measured counts from
the same region in the transmission scans without and with
the patient. The multiplicative attenuation correction factor
for the geometric mean quantitative method is the square
root of the region without-to-with count ratio, raised to the
power μ140/μ122 to convert from
57Co to
99mTc attenuation,
where μ140 and μ122 are the mass attenuation coefficients
for
99mTc and
57Co, respectively. Finally, the attenuation-
corrected counts were converted to fraction of injected
activity by dividing by the administered activity and the
camera sensitivity (counts per microcurie) measured with a
reference source of known
99mTc activity in a 10-ml vial
acquired in each patient whole-body scan.
For all organs except the bladder, the residence time was
calculated from the integral of either a single or biexpo-
nential function that had been fitted to the least-squares fit
of the estimated fraction of injected activity as a function of
time. The residence time for the bladder was estimated
using the Medical Internal Radiation Dose (MIRD) dynam-
ic bladder model with a 2-h voiding interval and a single
or biexponential fit of the remainder of the body (total
minus all organs) plus bladder contents fraction of injected
activity versus time as the input function. The choice of a
2-h voiding interval was based on the requirement that
the patient void immediately before each of the 2-, 4- and
6-h whole-body scans. The use of the remainder of the
body plus bladder contents activity as the input function
was based on the reasonable assumption that excretion of
99mTc-EC-DG is predominantly urinary, and all EC-DG not
accumulated in the organs would eventually be excreted in
the urine. Radiation absorbed dose estimates were calcu-
lated using the MIRD methodology. The residence times
were entered into the MIRDOSE version 3.1 personal
computer program for implementation of the MIRD
absorbed dose calculations, and the resulting unit absorbed
dose, effective dose equivalent and effective dose estimates
were tabulated [17–20].
Blood clearance
Blood samples (2 ml volume) were collected from all patients
at approximately 5, 15, 20, 30 and 45 min, and 1, 2, 4, 6 and
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99mTc-EC-DG. A baseline sample was
also drawn from each patient approximately 30 min before
injection of
99mTc-EC-DG. The times of the actual sample
collections were recorded and used for data analysis.
Aliquots (100 µl) were drawn from each blood sample and
radioactivity was assayed using a Cobra II gamma counter
(Packard Instrument Co., Meriden, CT). Data were recorded
as counts per minute with decay correction, to allow as-
sessment of biologic clearance from the blood. A calibration
standard of equivalent volume was counted for conversion
from counts per minute to microcuries. The data are
expressed as percentage of injected dose per gram of blood.
Safety
Vital signs including heart rate, respiratory rate, blood
pressure and temperature were monitored at four time
points: approximately 1.5 h before and 1, 4, and 17–24 h
after the bolus injection of
99mTc-EC-DG. Samples for
potassium, calcium, and magnesium levels were drawn at
three time points: approximately 1 h before, 10 min before,
and 80 min after the bolus injection of
99mTc-EC-DG.
Twelve-lead electrocardiography (ECG) was performed at
three time points: approximately 1 h before, time 0, and
1.5 h after the bolus injection of
99mTc-EC-DG. At the time
of each ECG, patient symptoms and medications were
documented as well. A board-certified cardiologist inter-
Target organ Absorbed dose (mGy/MBq, mean±SD)
Adrenals 0.0033±0.0009
Brain 0.0015±0.0007
Breasts 0.0016±0.0005
Gallbladder 0.0034±0.0010
Lower large intestine 0.0033±0.0009
Small intestine 0.0029±0.0008
Stomach 0.0084±0.0071
a
Upper large intestine 0.0029±0.0009
Heart wall 0.0028±0.0009
Kidneys 0.0123±0.0037
Liver 0.0047±0.0017
Lungs 0.0056±0.0009
Muscle 0.0021±0.0006
Ovaries 0.0041±0.0005
Pancreas 0.0039±0.0015
Red marrow 0.0022±0.0007
Bone surfaces 0.0036±0.0012
Skin 0.0013±0.0005
Spleen 0.0045±0.0023
a
Testes 0.0067±0.0029
Thymus 0.0021±0.0008
Thyroid 0.0063±0.0031
a
Urinary bladder 0.0247±0.0090
Uterus 0.0053±0.0006
Total body 0.0024±0.0007
Effective dose equivalent (mSv/MBq
b) 0.0062±0.0007
Effective dose (mSv/MBq
c) 0.0059±0.0011
Table 1 Absorbed dose for
each target organ
aBased on doses in all seven
patients, including patients with
no uptake in the organ (one for
stomach and thyroid; three for
spleen).
bICRP Publication 26, 1977.
cICRP Publication 60, 1990.
Table 2 Source organ residence times
Source organ Residence time (h, mean±SD)
Stomach 0.22±0.21
a
Kidneys 0.21±0.07
Liver 0.25±0.12
Lungs 0.28±0.05
Spleen 0.03±0.02
b
Testes 0.02±0.01
b
Thyroid 0.01±0.004
a
Urinary bladder contents 0.47±0.15
Remainder 2.78±1.07
aGreater than zero in only six of seven patients.
bGreater than zero in only four of seven patients (testes only
applicable to the four male patients).
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dermatologic reactions such as bruising, allergic reactions/
hypersensitivity, and wound infection immediately after
injection of
99mTc-EC-DG and then approximately 1, 3, and
5 h later. Patients were also contacted by a nurse
approximately 96 h after injection of
99mTc-EC-DG to
report any adverse reactions that may have occurred in the
interim.
Results
Total number of patients
The clinical trial was closed after 16 months (24 May 2004)
and the available data and results from the seven patients
treated with
99mTc-EC-DG (four men and three women;
median age 69 years, range 52–78 years) were submitted to
the FDA for review.
Radiation dosimetry
Target organs The organ estimated to receive the highest
dose was the bladder wall, with an average absorbed dose
among the seven patients of 2.47×10
−2 mGy/MBq
(9.12×10
−2 rad/mCi). The kidneys were estimated to receive
the second highest absorbed dose, 1.23×10
−2 mGy/MBq
(4.56×10
−2 rad/mCi). Table 1 shows the average and
standard deviation (SD) of absorbed dose for all target
organs calculated over all seven patients. Average and SD of
residence time for the defined source organs of activity and
the remainder of the body are tabulated in Table 2.
Effective dose equivalent and effective dose The mean
effective dose equivalent over all seven patients was
6.20×10
−3 mSv/MBq, or 6.89 mSv for administration of
1,110 MBq (30 mCi) activity, and the mean effective dose
was 5.90×10
−3 mSv/MBq, or 6.54 mSv for 1,110 MBq
(30 mCi).
Blood clearance
An average blood time–activity curve was calculated from
the pooled blood sample data of all seven patients (Fig. 2).
The clearance of
99mTc-EC-DG from the blood was rapid
and biphasic, dropping below 0.005% of the administered
activity by 1 h after injection.
Fig. 2 The composite time–activity curve for
99mTc-EC-DG in blood
for all seven patients. The percentage of the injected dose per gram of
blood (%ID/g) is presented as a function of the time elapsed since
injection of
99mTc-EC-DG. The plot extends only out to 6 h, to better
separate the high density of data points within the first hour
Fig. 3 Anterior whole-body
images of
99mTc-EC-DG in a
patient with NSCLC in the right
upper lung (arrow), obtained
after administration of 925 MBq
(25 mCi). The images were
acquired (from left to right)
immediately, and 2, 4, 6 and
24 h after injection. Each image
is self-normalized for display for
better visualization of the bio-
distribution at each time point
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None of the patients suffered a serious adverse event related
to the
99mTc-EC-DG. One patient developed minimal
erythema at the injection site which self-resolved within
an hour. No vital sign, electrolyte or ECG abnormality was
attributed to the administration of
99mTc-EC-DG.
Biodistribution – whole-body scans
Uptake of
99mTc-EC-DG was visualized primarily in the
blood pool, kidneys, bladder and liver in all seven patients.
Uptake was also seen secondarily in the stomach (six
patients), thyroid (six patients), testes (all four male
patients), spleen (four patients) and gastrointestinal tract
(mostly in the 6- to 24-h images). The primary lung lesion
Fig. 4 CT attenuation-corrected
SPECT transverse slices
obtained after administration of
925 MBq (25 mCi) of
99mTc-
EC-DG in a patient with
NSCLC in the medial posterior
right upper lung (solid arrow).
Uptake is also seen in the blood
pool (great vessels, dashed
arrows). The three images (left,
from top to bottom) are from the
2-, 4- and 6-h SPECT scans,
respectively (right reference
CT slice shown for anatomical
correlation)
Table 3
99mTc-EC-DG SPECT and
18F-FDG PET T:B uptake ratios
Patient
99mTc-EC-DG
18F-FDG
2-h 4-h 6-h
1 3.49 4.19 4.24 29.48
2 4.87 6.62 3.68 29.63
3 2.61 2.83 3.22 18.61
4
a 3.76 – 2.95 11.79
5
b – 3.85 – 19.84
6 2.53 2.54 3.67 13.54
aSPECT scans acquired at 2, 6 and 7.5 h (no 4-h scan, and 7.5-h scan
was excluded).
bSPECT scan at 4 h.
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patients. No uptake was visualized in either the brain or the
myocardium in any of the seven patients. The biodistribu-
tion of
99mTc-EC-DG over time in a representative patient
is illustrated in Fig. 3.
Tumor uptake – SPECT imaging
The primary tumor was grossly visualized with
99mTc-EC-
DG SPECT in six of the seven patients, with the 4-
h SPECT scan generally providing the highest contrast
relative to the surrounding tissue (Fig. 4). The
18F-FDG-
PET scan of the primary tumor was positive in all seven
patients. All of the patients were reported to have primary
NSCLC on the biopsy specimen. On lobectomy, one patient
(for whom
18F-FDG PET was positive and
99mTc-EC-DG
SPECT was negative) was pathologically documented to
have histoplasma capsulatum with a necrotic calcified
granuloma; initial biopsy of the site was falsely positive.
Evidence of anthrasis and an old fibrotic granuloma were
found in the patient’s mediastinum.
A patient-by-patient comparison of T:B ratios between
the 2-, 4- and 6-h
99mTc-EC-DG SPECT and
18F-FDG PET
scans for the six patients with tumor uptake of
99mTc-EC-
DG is shown in Table 3. The T:B ratios were (mean±SD)
3.45±0.96, 4.01±1.61, 3.55±0.49 and 20.48±7.65, for the 2-,
4- and 6-h
99mTc-EC-DG SPECT and
18F-FDG PET scans,
respectively.
The granuloma enhanced on the
18F-FDG PET scan,
with a T:B ratio of 7.94. The granuloma showed no uptake
on the 2-, 4-, and 6-h
99mTc-EC-DG SPECTscans, with T:B
ratios of 0.99, 1.02, and 0.96, respectively .
Discussion
Radiation dosimetry and pharmacokinetics
The biodistribution of
99mTc-EC-DG showed its major
route of excretion to be through the kidneys (Fig. 3). The
compound has a very low molecular weight (591 Da) and
was rapidly cleared from the blood, as shown by the plasma
time–activity curve (Fig. 2). Nontarget tissues exhibited
rapid washout of the tracer resulting in increasing T:B count
density ratios over time.
The presence of multiple hydroxyl groups makes the
compound highly hydrophilic. This hydrophilicity increases
its renal clearance. The hydrophilicity also limits passive
diffusion of
99mTc-EC-DG through cell membranes, leading
to our hypothesis that the accumulation seen in tissues is
related to active transport through transporters, receptors, or
molecular interactions between EC sulfhydryl groups and
cell-associated proteins. The hydrophilicity may also
prevent
99mTc-EC-DG from freely crossing membranes
such as the blood–brain barrier, and limit accumulation of
99mTc-EC-DG in normal brain tissue. We have previously
reported that tumor uptake of
99mTc-EC-DG is most likely
via a process related to glucose metabolism [9, 14]. It
should be noted, however, that there are at least five
glucose transporters. Glucose transporters 1 and 3 are
localized in brain tissue. Poor brain uptake of radiolabeled
glucosamine has been also reported by others [21]. The
observation that uptake of
99mTc-EC-DG is low in the
brain and heart of human subjects increases the possibility
for metal-therapeutic and radio-therapeutic applications of
EC-DG.
Safety and clinical findings
Imaging of primary NSCLC tumors with 9.25×10
2 MBq
(25 mCi) of
99mTc-EC-DG appears to be feasible and safe.
The effective dose equivalent for 1,110 MBq (30 mCi) of
99mTc-EC-DG (i.e., the same as that typically administered
for a
99mTc bone scan) would be 6.89 mSv. This compares
to 9.99 mSv for a nominal 370 MBq (10 mCi) of an
18F-
FDG PET scan [22].
99mTc-EC-DG had acceptable biodis-
tribution, and did accumulate in the primary tumor of all six
patients with confirmed NSCLC and concordant accumu-
lation of
18F-FDG (visualized best in the 4-h SPECT scans
in this study). In addition, the administration of
99mTc-EC-
DG was well tolerated in this cohort of patients.
Conclusion
The novel radiopharmaceutical
99mTc-EC-DG appears to be
safe and to have acceptable dosimetric and biodistribution
properties for a diagnostic nuclear medicine imaging agent.
This conclusion is based on the lack of serious adverse
reactions, a biodistribution not unusual for a diagnostic
radiopharmaceutical and to some extent similar to that of
18F-FDG, an effective dose equivalent similar to that of
99mTc-methylene diphosphonate (MDP) (6.10×10
−3 mSv/
MBq) and less than that of
18F-FDG (3.00×10
−2 mSv/
MBq), and tumor uptake three to four times that in normal
tissue. Larger studies are planned to further evaluate the
diagnostic potential of this agent.
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